The topoisomerase II inhibitor VM-26 induces marked changes in histone H1 kinase activity, histones H1 and H3 phosphorylation, and chromosome condensation in G2 phase and mitotic BHK cells.
We have examined the effects of topoisomerase inhibitors on the phosphorylation of histones in chromatin during the G2 and the M phases of the cell cycle. Throughout the G2 phase of BHK cells, addition of the topoisomerase II inhibitor VM-26 prevented histone H1 phosphorylation, accompanied by the inhibition of intracellular histone H1 kinase activity. However, VM-26 had no inhibitory effect on the activity of the kinase in vitro, suggesting an indirect influence on histone H1 kinase activity. Entry into mitosis was also prevented, as monitored by the absence of nuclear lamina depolymerization, chromosome condensation, and histone H3 phosphorylation. In contrast, the topoisomerase I inhibitor, camptothecin, inhibited histone H1 phosphorylation and entry into mitosis only when applied at early G2. In cells that were arrested in mitosis, VM-26 induced dephosphorylation of histones H1 and H3, DNA breaks, and partial chromosome decondensation. These changes in chromatin parameters probably reverse the process of chromosome condensation, unfolding condensed regions to permit the repair of strand breaks in the DNA that were induced by VM-26. The involvement of growth-associated histone H1 kinase in these processes raises the possibility that the cell detects breaks in the DNA through their effects on the state of DNA supercoiling in constrained domains or loops. It would appear that histone H1 kinase and topoisomerase II work coordinately in both chromosome condensation and decondensation, and that this process participates in the VM-26-induced G2 arrest of the cell.
Roberge
M
M
Department of Biological Chemistry, School of Medicine, University of California, Davis 95616.
Th'ng
J
J
Hamaguchi
J
J
Bradbury
E M
EM
D000818:Animals; D016590:Aphidicolin; D002453:Cell Cycle / Q000187:drug effects; D002478:Cells, Cultured; D002875:Chromosomes / Q000187:drug effects / Q000378:metabolism*; D004249:DNA Damage; D004250:DNA Topoisomerases, Type II / Q000502:physiology*; D003703:Demecolcine / Q000494:pharmacology; D004224:Diterpenes / Q000494:pharmacology; D016193:G1 Phase; D016195:G2 Phase / Q000502:physiology; D006657:Histones / Q000378:metabolism*; D008677:Metaphase / Q000502:physiology; D008938:Mitosis / Q000502:physiology; D009685:Nuclear Envelope / Q000378:metabolism; D010766:Phosphorylation; D006656:Protamine Kinase / Q000187:drug effects / Q000378:metabolism*; D013713:Teniposide / Q000494:pharmacology*; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
D004224:Diterpenes; D006657:Histones; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D016590:Aphidicolin; D013713:Teniposide; D006656:Protamine Kinase; D004250:DNA Topoisomerases, Type II; D003703:Demecolcine